参考文献
[1] Finn RS, Qin SK, Ikeda M, et al. Atezolizumab plus bevacizumab
in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020,
382(20): 1894-1905. DOI: 10.1056/NEJMoa1915745.
[2] Cheng A, Qin S, Ikeda M, et al. Atezolizumab + bevacizumab vs
sorafenib in patients with unresectable hepatocellular carcinoma:
phase 3 results from IMbrave150[C]. ESMO Asia Congress, 2019:
abstract LBA1.
[3] Xu J, Shen J, Gu S. et al. Camrelizumab in combination with
apatinib in patients with advanced hepatocellular carcinoma
(RESCUE): a nonrandomized, open-label, phase II trial[J]. Clin
Cancer Res, 2021, 27(4): 1003-1011. DOI: 10.1158/1078-0432.
CCR-20-2571.
[4] Qin S, Ren Z, Feng Z, et al. Efficacy and safety of atezolizumab+
bevacizumab vs sorafenib in Chinese patients with unresectable
HCC in the phase Ⅲ IMbrave150 study[C]. Liver Cancer Summit,
2020: abstract OP02-03.
[5] Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib
plus pembrolizumab in patients with unresectable hepatocellular
carcinoma[J]. J Clin Oncol, 2020, 38(26): 2960-2970. DOI: 10.1200/
JCO.20.00808.
[6] kudo M, Ikeda M, Motomura K, et al. A phase 1b study of lenvatinib
plus nivolumab in patients with unresectable hepatocellular carcinoma
(study 117)[C]. ASCO Gastrointestinal Cancers Symposium, 2020:
Abstract 513.
[7] Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk
factors in China and its provinces, 1990-2017: a systematic analysis
for the Global Burden of Disease Study 2017[J]. Lancet, 2019,
394(10204): 1145-1158. DOI: 10.1016/S0140-6736(19)30427-1.
[8] Allemani C, Weir Hk, Carreira H, et al. Global surveillance of
cancer survival 1995-2009: analysis of individual data for 25, 676,
887 patients from 279 population-based registries in 67countries[J].
Lancet, 2015, 385(9972): 977-1010. DOI: 10.1016/S0140-
6736(14)62038-9.
[9] Torre LA, Bray F, Siegel R et al. Global cancer statistics, 2012[J].
CA Cancer J Clin, 2015, 65(2): 87-108. DOI: 10.3322/caac.21262.
[10] Chen W, Zheng R, Baade Pd, et al. Cancer statistics in China,
2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/
caac.21338.
[11] Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global
cancer incidence and mortality in 2018: GLOBOCAN sources and
methods. Int J Cancer, 2019, 144(8): 1941-1953. DOI: 10.1002/
ijc.31937.
[12] Lovet J, Ricci S, Vincenzo M, et al. Sorafenib in advanced
hepatocellular carcinoma[J]. N Engl J Med, 2008, 359 (4): 378-390.
DOI: 10.1056/NEJMoa0708857.
[13] Cheng A, Kang Y, Chen Z, et al. Efficacy and safety of sorafenib
in patients in the Asia-Pacific region with advanced hepatocellular
carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled
trial[J]. Lancet Oncol, 2009, 10 (1): 25-34. DOI: 10.1016/S1470-
2045(08)70285-7.
[14] Kudo M, Finn R, Qin S, et al. Lenvatinib versus sorafenib in first-
line treatment of patients with unresectable hepatocellular carcinoma:
a randomised phase 3 non-inferiority trial[J]. Lancet. 2018,
391(10126): 1163-1173. DOI: 10.1016/S0140-6736(18)30207-1.
[15] Bruix J, Qin S, Merle P, et al. Regorafenib for patients with
hepatocellular carcinoma who progressed on sorafenib treatment
(RESORCE): a randomised, double-blind, placebo-controlled, phase
3 trial[J]. Lancet, 2017, 389(10064): 56-66. DOI: 10.1016/S0140-
6736(16)32453-9.
[16] Aboualfa G, Meyer T, Cheng A, et al. Cabozantinib in patients with
advanced and progressing hepatocellular carcinoma[J]. N Engl J
Med, 2018, 379(1): 54-63. DOI: 10.1056/NEJMoa1717002.
[17] Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib
in patients with advanced hepatocellular carcinoma and increased
α-fetoprotein concentrations (REACH-2): a randomised, double-
blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019,
20(2): 282-296. DOI: 10.1016/S1470-2045(18)30937-9.
[18] 中华人民共和国国家卫生健康委员会医政医管局 . 原发性肝癌
诊疗规范 (2019 年版 )[J]. 中国实用外科杂志 , 2020, 40(2): 121-
138.
[19] 中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤学会
（CSCO）原发性肝癌诊疗指南 2020[M]. 北京 : 人民卫生出版社 ,
2020.
[20] Ren Z, Fan J, Xu J, et al. Sintilimab plus bevacizumab biosimilar
vs sorafenib as first-line treatment for advanced hepatocellular
carcinoma (ORIENT-32)[C]. ESMO Asia Virtual Congress, 2020:
LBA2.
[21] Qin S, Chen Z, Liu Y, et al. A phase Ⅱ study of anti-PD-1 antibody
camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy
as first-line therapy for advanced hepatocellular carcinoma or biliary
tract cancer[J]. J Clin Oncol, 2019, 37 (s): abstract 4074.
[22] Zhu A, Finn R, Edeline J, et al. Pembrolizumab in patients with
advanced hepatocellular carcinoma previously treated with
sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2
trial[J]. Lancet Oncol, 2018, 19(7): 940-952. DOI: 10.1016/S1470-
2045(18)30351-6.
[23] Jiao SC, Bai L, Dong JH, et al. Clinical activity and safety of
penpulimab (Anti-PD-1) with anlotinib as first-line therapy for
advanced hepatocellular carcinoma (HCC)[J]. J Clin Oncol, 2020,
38(15_suppl):4592. DOI:10.1200/JCO.2020.38.15_suppl.4592.
[24] Hui-Chuan S, Xiao-Dong Z, Cheng H, et al. Initially unresectable
hepatocellular carcinoma treated by combination therapy of tyrosine
kinase inhibitor and anti-PD-1 antibody followed by resection[C].
2020 ASCO Annual Meeting, 2020.
[25] 张雯雯 , 胡丙洋 , 韩骏 , 等 . PD-1 抑制剂与多靶点酪氨酸激酶
抑制剂联合方案用于进展期肝癌转化治疗研究的初步报告 [J].
中华肝胆外科杂志 , 2020, 26(12): 947-948. DOI: 10.3760/cma.
j.cn113884-20201203-00611.
[26] Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously
treated hepatocellular carcinoma: a multicenter, randomized, open-
label, parallel-group, phase 2 trial[J]. Lancet Oncol, 2020, 21(4): 571-
580. DOI: 10.1016/S1470-2045(20)30011-5.
[27] Michel D, Ghassan A, Ren Z, et al. Results from a global Phase 2
study of tislelizumab, an investigational PD-1 antibody, in patients
with previously treated advanced hepatocellular carcinoma[C].
WCGI, 2021: O-1.
[28] Bruix J, Fonseca L, Reig M. Insights into the success and failure
of systemic therapy for hepatocellular carcinoma[J]. Nat Rev
Gastroenterol Hepatol, 2019, 16(10): 617-630. DOI: 10.1038/
s41575-019-0179-x.
[29] Llovet J, Kelley R, Villanueva A, et al. Hepatocellular carcinoma[J].
Nat Rev Dis Primers, 2021, 7(1): 6. 41572-020-00240-3. DOI:
10.1038/s41572-020-00240-3.
[30] Ei-khoueiry A, Sangro B, Yau T, et al. Nivolumab in patients with
advanced hepatocellular carcinoma (CheckMate 040): an open-label,
non-comparative, phase 1/2 dose escalation and expansion trial[J].
Lancet, 2017, 389 (10088): 2492-2502. DOI: 10.1016/S0140-
6736(17)31046-2.
[31] Finn R, Ryoo B, Merle P, et al. Pembrolizumab as second-line
therapy in patients with advanced hepatocellular carcinoma in
KEYNOTE-240: a randomized, double-blind, phase III trial[J]. J
Clin Oncol, 2020, 38(3): 193-202. DOI: 10.1200/JCO.19.01307.
[32] Xu J, Zhang Y, Jia R, et al. Anti-PD-1 antibody SHR-1210 combined
with apatinib for advanced hepatocellular carcinoma, gastric, or
esophagogastric junction cancer: an open-label, dose escalation and
expansion study[J]. Clin Cancer Res, 2019, 25(2): 515-523. DOI:
10.1158/1078-0432.CCR-18-2484.
[32] Shen L, Guo J, Zhang Q, et al. Tislelizumab in Chinese patients with
advanced solid tumors: an open-label, non-comparative, phase 1/2
study[J]. J Immunother Cancer, 2020, 8(1): e000437. DOI: 10.1136/
jitc-2019-000437.
[33] Yau T, Kang Y, Kim T, et al. Efficacy and safety of nivolumab plus
ipilimumab in patients with advanced hepatocellular carcinoma
previously treated with sorafenib: the checkmate 040 randomized
clinical trial[J]. JAMA Oncol. 2020, 6(11): e204564. DOI: 10.1001/
jamaoncol.2020.4564.
[34] Kelley R, Sangro B, Harris W, et al. Efficacy, tolerability, and
biologic activity of a novel regimen of tremelimumab in combination
with durvalumab for patients with advanced hepatocellular
carcinoma[J]. J Clin Oncol, 2020, 37(S): 4508. DOI: 10.1200/
JCO.2020.38.15_suppl.4508.
[35] Mrl L, Nipp R, Muzikansky A, et al. Impact of age on outcomes
with immunotherapy in patients with non-small cell lung
cancer[J]. J Thorac Oncol，2019, 14(3): 547-552. DOI: 10.1016/
j.jtho.2018.11.011.
[36] Wolchok J, Hoos A, O'Day S, et al. Guidelines for the evaluation of
immune therapy activity in solid tumors: immune-related response
criteria[J]. Clin Cancer Res, 2009, 15(23): 7412-7420. DOI:
10.1158/1078-0432.CCR-09-1624.
[37] Somarouthu B, Lee S, Urban T, et al. Immune-related tumour
response assessment criteria: a comprehensive review[J]. Br J
Radiol, 2018, 91(1084): 20170457. DOI: 10.1259/bjr.20170457.
[38] Cook M, Kim C. Safety and efficacy of immune checkpoint inhibitor
therapy in patients with HIV infection and advanced-stage cancer:
a systematic review[J]. JAMA Oncol 2019, 5(7): 1049-1054. DOI:
10.1001/jamaoncol.2018.6737.
[39] 中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤学会 (CSCO)
免疫检查点抑制剂相关的毒性管理指南 [M]. 北京 : 人民卫生出
版社 , 2019.
[40] Michot J, Bigenwald C, Champiat S, et al. Immune-related adverse
events with immune checkpoint blockade: a comprehensive
review[J]. Eur J Cancer, 2016, 54: 139-148. DOI: 10.1016/
j.ejca.2015.11.016.
[41] Pillai R, Behera M, Owonikoko T, et al. Comparison of the toxicity
profile of PD-1 versus PD-L1 inhibitors in non-small cell lung
cancer: a systematic analysis of the literature[J]. Cancer, 2018,
124(2): 271-277. DOI: 10.1002/cncr.31043.
[42] 中华医学会感染病学分会 , 中华医学会肝病学分会 . 慢性乙型
肝炎防治指南 (2019 年版 )[J]. 中华传染病杂志 , 2019, 37(12):
711-736. DOI: 10.3760/cma.j.issn.1000-6680.2019.12.003.
[43] 中华医学会肝病学分会 , 中华医学会感染病学分会 . 丙型肝炎
防治指南 (2019 年版 )[J]. 中华临床感染病杂志 , 2019, 12(6):
429-450. DOI: 10.3760/cma.j.issn.1007-3418.2019.12.008.
[44] Pawlotsky J, Negro F, Aghemo A, et al. EASL recommendations on
treatment of hepatitis C 2018[J]. J Hepatol, 2018, 69 (2): 373-395.
DOI: 10.1016/j.jhep.2018.03.026.
[45] Kim W, Loomba R, Berg T, et al. Impact of long-term tenofovir
disoproxil fumarate on incidence of hepatocellular carcinoma in
patients with chronic hepatitis B[J]. Cancer, 2015, 121 (20): 3631-
3638. DOI: 10.1002/cncr.29537.
[46] Huang G, Lau W, Wang Z, et al. Antiviral therapy improves
postoperative survival in patients with hepatocellular carcinoma: a
randomized controlled trial[J]. Ann Surg, 2015, 261 (1): 56-66. DOI:
10.1097/SLA.0000000000000858.
[47] Papatheodoridis G, Idilman R, Dalekos G, et al. The risk of
hepatocellular carcinoma decreases after the first 5 years of entecavir
or tenofovir in Caucasians with chronic hepatitis B[J]. Hepatology,
2017, 66 (5): 1444-1453. DOI: 10.1002/hep.29320.
[48] Chan H, Fung S, Seto W, et al. Tenofovir alafenamide versus
tenofovir disoproxil fumarate for the treatment of HBeAg-positive
chronic hepatitis B virus infection: a randomised, doubleblind, phase
3, non-inferiority trial[J]. Lancet Gastroenterol Hepatol, 2016, 1 (3) :
185-195. DOI: 10.1016/S2468-1253(16)30024-3.
[49] Buti M, Gane E, Seto W, et al. Tenofovir alafenamide versus tenofovir
disoproxil fumarate for the treatment of patients with HBeAg-negative
chronic hepatitis B virus infection: a randomised, double-blind, phase
3, non-inferiority trial[J]. Lancet Gastroenterol Hepatol, 2016, 1 (3):
196-206. DOI: 10.1016/S2468-1253(16)30107-8.
[50] 中华医学会肝病学分会肝炎学组 , 中华肝脏病杂志 . 非一线核
苷 ( 酸 ) 类似物经治慢性乙型肝炎患者治疗策略调整专家共识
[J]. 中华肝脏病杂志 , 2019, 27 (5) : 343-346. DOI: 10.3760/cma.
j.issn.1007-3418.2019.05.004.
[51] Santini F, Rizvi H, Plodkowski A, et al. Safety and efficacy of re-
treating with immunotherapy after immune-related adverse events
in patients with NSCLC[J]. Cancer Immunol Res, 2018, 6(9): 1093-
1099. DOI: 10.1158/2326-6066.CIR-17-0755.
[52] National Comprehensive Cancer Network. Management of
Immunotherapy-related Toxicities[C]. NCCN Guidelines Version 1,
2020. DOI: 10.6004/jnccn.2020.0012.
[53] Lee Y, Lee J, Lee J, et al. Hepatocellular carcinoma: diagnostic
performance of multidetector CT and MR imaging-a systematic
review and meta-analysis[J]. Radiology, 2015, 275(1): 97-109. DOI:
10.1148/radiol.14140690.
[54] Liu X, Jiang H, Chen J, et al. Gadoxetic aciddisodium-enhanced magnetic
resonance imaging outperformed multidetector computed tomography
in diagnosing small hepatocellular carcinoma:a meta-analysis[J]. Liver
Transpl, 2017, 23(12): 1505-18. DOI: 10.1002/lt.24867.
[55] Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation
criteria in solid tumours: revised RECIST guideline[J]. Eur J Cancer,
2009, 45(2): 228-247. DOI: 10.1016/j.ejca.2008.10.026.
[56] Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response
after locoregional therapies in hepatocellular carcinoma: are response
evaluation criteria in solid tumors reliable?[J]. Cancer, 2009, 115(3):
616-623. DOI: 10.1002/cncr.24050.
[57] Lencioni R, Llovet J. Modified RECIST assessment for
hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30(1): 52-60.
DOI: 10.1055/s-0030-1247132.
[58] Sato Y, Watanabe H, Sone M, et al. Tumor response evaluation
criteria for HCC (hepatocellular carcinoma) treated using TACE:
RECIST version 1.1 and mRECIST: JIVROSG-0602[J]. Ups J Med
Sci, 2013, 118(4): 16-22. DOI: 10.3109/03009734.2012.729104.
[59] Kudo M, Ikeda M, Ueshima K, et al. Response evaluation criteria
in cancer of the liver version 5 (RECICL 2019 revised version)[J].
Hepatol Res, 2019, 49(9): 981-989. DOI: 10.1111/hepr.13394.
[60] Mamdani H, Wu H, Oneil B, et al. Excellent response to Anti-PD-1
therapy in a patient with hepatocellular carcinoma: case report and
review of literature[J]. Discov Med, 2017, 23(128): 331-336. PMID:
28715649.
[61] Grierson P, Crites D, Ruzinova MB, et al. Distinct clinical and
magnetic resonance features of metastatic hepatocellular carcinoma
treated with pembrolizumab: a case report of late response after
pseudoprogression[J]. Hepatol Commun, 2017, 2(2): 148-151. DOI:
10.1002/hep4.1132.
[62] Champiat S, Dercle L, Ammari S. et al. Hyperprogressive disease
is a new pattern of progression in cancer patients treated by anti-
PD-1/PD-L1[J]. Clin Cancer Res, 2017, 23(8): 1920-1928. DOI:
10.1158/1078-0432.CCR-16-1741.
[63] Kato S, Goodman A, Walavalkar V, et al. Hyperprogressors after
immunotherapy: analysis of genomic alterations associated with
accelerated growth rate[J]. Clin Cancer Res, 2017, 23(15): 4242-
4250. DOI: 10.1158/1078-0432.CCR-16-3133.
[64] SBouzid E, Defaucheux C, Karabajakian A, et al. Hyperprogression
during anti-PD-1/PD-L1 therapy in patients with recurrent and/or
metastatic head and neck squamous cell carcinoma[J]. Ann Oncol,
2017, 28(7): 1605-1611. DOI: 10.1093/annonc/mdx178.
[65] Ferrara R, Mezquita L, Texier M. et al. Hyperprogressive disease in
patients with advanced non-small cell lung cancer treated with PD-1/
PD-L1 inhibitors or with singleagent chemotherapy[J]. JAMA Oncol,
2018, 4(11): 1543-1552. DOI: 10.1001/jamaoncol.2018.3676.
[66] Kim C, Kim K, Pyo K, et al. Hyperprogressive disease during PD-1/
PD-L1 blockade in patients with non-small-cell lung cancer[J]. Ann
Oncol, 2019, 30(7): 1104-1113. DOI: 10.1093/annonc/mdz123.
[67] Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for
response criteria for use in trials testing immunotherapeutics[J].
Lancet Oncol, 2017, 18 (3): e143-e152. DOI: 10.1016/S1470-
2045(17)30074-8.
[68] Petrioli R, Mazzei M, Giorgi S, et al. Hyperprogressive disease
in advanced cancer patients treated with nivolumab: a case series
study[J]. Anticancer Drugs, 2020, 31(2): 190-195. DOI: 10.1097/
CAD.0000000000000864.
[69] Tanaka Y, Matsubara O, Asada K, et al. Hyperprogressive disease
after treatment with pembrolizumab in lung adenocarcinoma: an
autopsy case study[J]. Respir Med Case Rep, 2019, 28: 100885.
DOI: 10.1016/j.rmcr.2019.100885.
[70] Wong D, Lee J, Choo S, et al. Hyperprogressive disease in
hepatocellular carcinoma with immune checkpoint inhibitor use: a
case series[J]. Immunotherapy, 2019, 11(3): 167-175. DOI: 10.2217/
imt-2018-0126.
[71] Trevisani F, D’Intino P, Morselli-Labate A, et al. Serum α-fetoprotein
for diagnosis of hepatocellular carcinoma in patients with chronic
liver disease: influence of HBsAg and anti-HCV status[J]. J Hepatol,
2001, 34 (4): 570-575. DOI: 10.1016/s0168-8278(00)00053-2.
[72] Yi X, Yu S, Bao Y. Alpha-fetoprotein-L3 in hepatocellular
carcinoma: a meta-analysis[J]. Clinica Chimica Acta , 2013, 425(21):
212-220. DOI: 10.1016/j.cca.2013.08.005.
[73] Park H, Park J. Clinical significance of AFP and PIVKA- Ⅱ
responses for monitoring treatment outcomes and predicting
prognosis in patients with hepatocellular carcinoma[J]. Biomed Res
Int, 2013, 21(4): 310427. DOI: 10.1155/2013/310427.
[74] 欧美同学会医师协会肝胆分会 , 中国研究性医院学会分子诊断
专委会 , 中国临床肿瘤学会肝癌专委会 , 等 . 肝胆肿瘤分子诊断
临床应用专家共识 [J]. 中华肝胆外科杂志 , 2020, 26 (2): 81-89.
DOI: 10.3760/cma.j.issn.1007-8118.2020.02.001.
联系客服
